Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa)
CANCER RESEARCH(2022)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined